Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential responses of APC-mutant CRCs to chemotherapy are not well understood. We report that expression of the transcription factor prospero homeobox 1 (PROX1) was reduced in desmoplastic APC-mutant human CRCs. In genetic Apc-mutant mouse models, loss of Prox1 promoted the growth of desmoplastic, angiogenic, and immunologically silent tumors through derepression of Mmp14. Although chemotherapy inhibited Prox1-proficient tumors, it promoted further stromal activation, angiogenesis, and invasion in Prox1-deficient tumors. Blockade of vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) combined with CD40 agonistic antibodies promoted antiangiogenic and immunostimulatory reprogramming of Prox1-deficient tumors, destroyed tumor fibrosis, and unleashed T cell-mediated killing of cancer cells. These results pinpoint the mechanistic basis of chemotherapy-induced hyperprogression and illustrate a therapeutic strategy for chemoresistant and desmoplastic CRCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study targeting chemoresistant and desmoplastic colorectal cancer (CRC) cells by targeting vascular endothelial growth factor A (VEGFA) and angiopoietin‐2 (ANGPT2) along with the cluster of differentiation 40 (CD40) agonistic antibodies destroyed tumor fibrosis and induced T cell‐mediated killing [7].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“We further analyzed genome-wide transcriptional responses of tumors to A2V+aCD40 treatment using gene set enrichment analysis (GSEA) (53).”
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“It is effective in highly mutated MSI CRCs, in which the T cell response has already been elicited (67, 68).”
Identification of stem cells in small intestine and colon by marker gene Lgr5
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007) · Nature · doi:10.1038/nature06196 · Cited by 5,687 · cited 1×
“…genes leucine-rich repeat–containing G protein– coupled receptor 5 ( Lgr5 ), lymphoid enhancer binding factor 1 ( Lef1 ), ring finger protein 43 ( Rnf43 ), and Eph receptor B2 ( EphB2 ) (34–36) was decreased but not completely abolished upon loss of expression in desmoplastic CMS4 CRCs (Figure 1C).”
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 2×
“%) is characterized by low WNT signaling, a high proportion of stromal cells, prominent angiogenesis, and a poor prognosis (4).”
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · cited 11×
“We believe our results have broad implications for the development of novel therapies to treat APC -mutant MSS CRCs, which represent the majority of all CRC cases.”
InfluentialSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890 · cited 2×
“Enrichment was computed using single-sample GSEA (81).”
A global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491 · cited 1×
“To determine whether fibroblasts accelerate the progression of Prox1 -deficient tumors, we coimplanted AKP or AKPP organ-oids together with fluorescent intestinal fibroblasts isolated from mTmG + mice, in which all cells express the membrane-targeted tdTomato protein (41).”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“5-FU–based adjuvant chemotherapy is the standard of care for CRC and improves patient survival; however, a substantial proportion of the patients either do not respond to this treatment or relapse (2).”
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“Because CAF-mediated extracellular matrix (ECM) deposition and increased tumor stiffness promote tumor growth (42), we cultured organoids in synthetic hydrogels with a stiffness similar to that of either normal intestine (1.3 kPa) or CRC stroma (2.7 kPa), as described previously (43), in the…”
Influential
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“Another intriguing study in mouse colorectal cancer models showed that adaptive resistance to chemotherapy (5-FU and cisplatin) is associated with a pronounced stromal response and T-cell exclusion (291).”
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
“In a good example, blockade of VEGF alongside ANGPT2, when combined with CD40 agonistic antibodies, had an anti-angiogenic and immunostimulatory effect resulting in T-cell mediated killing of cancer cells in a colorectal tumor model [336].”
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Another study targeting chemoresistant and desmoplastic colorectal cancer (CRC) cells by targeting vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) along with the cluster of differentiation 40 (CD40) agonistic antibodies destroyed tumor fibrosis and induced T cell-mediated killing [7].”
BackgroundThe roles of tertiary lymphoid structures in chronic diseases
Sato, Y., Silina, K., van den Broek, M., Hirahara, K., & Yanagita, M. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00706-z · Cited by 320
“In a chemotherapy-resistant colorectal cancer model, the combination of antiangiogenic agents with agonistic anti-CD40 antibody induced vascular normalization, TLS development and T cell-mediated tumour control 125 .”
WNT signaling and cancer stemness
Katoh, M., & Katoh, M. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220016 · Cited by 179
Ju, W., Xia, R., Zhu, D., Dou, S., Zhu, G., Dong, M., Wang, L., Sun, Q., Zhao, T., Zhou, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33080-8 · Cited by 153
Martínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 119
Self-citationNovel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
“Not coincidentally, the treatment of mouse colorectal cancer with antibodies against A2V and CD40 promoted an increase in the number of effector T cells within the tumor tissue [53].”
BackgroundLeong, A., & Kim, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228689 · Cited by 102
Surowka, M., Schäfer, W. M., & Klein, C. (2021) · mAbs · doi:10.1080/19420862.2021.1967714 · Cited by 101
“mediated potent anti-tumoral and anti-angiogenic efficacy in various preclinical models as monotherapy and in combination with chemotherapy, as well as combined with PD-1 checkpoint inhibition and CD40 agonism.(105,106) Vanucizumab was generally well tolerated as a monotherapy in a Phase 1 clinical trial and demonstra…”
BackgroundMilestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 88
“…underscore the multifaceted role of VEGFA in the modulation of tumor-associated immunosuppression 44,150 and may help explain the therapeutic benefits of inhibiting angiogenic signaling in combination with therapeutic strategies aimed to stimulate immune responses against cancer 98,161,240,251 .”
Bui, T. M., Yalom, L. K., Ning, E., Urbanczyk, J. M., Ren, X., Herrnreiter, C. J., Disario, J. A., Wray, B. D., Schipma, M. J., Velichko, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174545 · Cited by 67
“Consistent with previous reports, MMP14 and OPN expression was also detected on tumor macrophages and EpCAM + tumor cells (38–41), however, at 2-to 3-fold lower levels compared with TANs (Supplemental Figure 6, K, L, O, and P), indicating TANs as a major source of MMP14 and OPN in the CRC tumor…”
ResultComprehensive Analysis of the Expression and Prognosis for MMPs in Human Colorectal Cancer
Yu, J., He, Z., He, X., Luo, Z., Lian, L., Wu, B., Lan, P., & Chen, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771099 · Cited by 67
Gonzalez‐Molina, J., Moyano‐Galceran, L., Single, A., Gultekin, O., Alsalhi, S., & Lehti, K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.012 · Cited by 59
Shi, J., Liu, C., Luo, S., Cao, T., Lin, B., Zhou, M., Zhang, X., Wang, S., Zheng, T., & Li, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104384 · Cited by 55
Neutrophils in the premetastatic niche: key functions and therapeutic directions
Jia, J., Wang, Y., Li, M., Wang, F., Peng, Y., Hu, J., Li, Z., Bian, Z., & Yang, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02107-7 · Cited by 45
“Moreover, another member of the matrix metallo-proteinase family, MMP-14, is also regarded as a potential therapeutic target, and researchers have discovered an antiangiogenic immunotherapy that inhibits MMP-14 that could overcome therapeutic resistance in colorectal cancer [133].”
BackgroundHow the matrix metalloproteinase MMP14 contributes to the progression of colorectal cancer
Claesson, L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135239 · Cited by 42
APC mutation correlated with poor response of immunotherapy in colon cancer
Li, B., Zhang, G., & Xu, X. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02725-3 · Cited by 39
Xue, X., Wang, X., Pang, M., Yu, L., Qian, J., Li, X., Tian, M., Lu, C. Y., Xiao, C., & Liu, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02452-1 · Cited by 34
The MMP14–caveolin axis and its potential relevance for lipoedema
Kruglikov, I. L., Joffin, N., & Scherer, P. E. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0395-z · Cited by 34
Li, D., Lin, F., Li, G., & Zeng, F. (2021) · Cytotechnology · doi:10.1007/s10616-021-00480-5 · Cited by 30
“Silencing of VEGFA could significantly promote the killing effect of T cells on colon cancer cells (Ragusa 2020).”
BackgroundMakutani, Y., Kawakami, H., Tsujikawa, T., Yoshimura, K., Chiba, Y., Ito, A., Kawamura, J., Haratani, K., & Nakagawa, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956270 · Cited by 31
“Frontiers in Oncology 02 clinical studies have shown that colorectal tumors with a relatively high MMP14 expression level tend to have a mesenchymal phenotype such as CMS4 (20, 32).”
BackgroundInfluentialNeutrophil granulocytes influence on extracellular matrix in cancer progression
Strøbech, J. E., Giuriatti, P., & Erler, J. T. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00122.2022 · Cited by 30
Zhao, Y., Fu, B., Chen, P., Li, Q., Ouyang, Q., Zhang, C., Cai, G., Wu, L., & Chen, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13055 · Cited by 29
Lef1 restricts ectopic crypt formation and tumor cell growth in intestinal adenomas
Heino, S., Fang, S., Lähde, M., Högström, J., Nassiri, S., Campbell, A. D., Flanagan, D. J., Raven, A., Hodder, M. C., Nasreddin, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0512 · Cited by 28
Self-citationApelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth
Bernier‐Latmani, J., Cisarovsky, C., Mahfoud, S., Ragusa, S., Dupanloup, I., Barras, D., Renevey, F., Nassiri, S., Anderle, P., Squadrito, M. L., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00061-5 · Cited by 27
Self-citationChemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer
Li, X., Li, K., Li, M., Lin, X., Mei, Y., Huang, X., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844648 · Cited by 28
Ang2-Targeted Combination Therapy for Cancer Treatment
Liu, N., Liu, M., Fu, S., Wang, J., Tang, H., Danbala, I. A., Chen, D., & Wang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.949553 · Cited by 26
“Immunotherapy Ang2 reduces the ability of the immune system (mainly T cells) to recognize and attack tumors by acting on immune cells (9, 87, 88).”
BackgroundPriming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors
Kim, D. J., Anandh, S., Null, J. L., Przanowski, P., Bhatnagar, S., Kumar, P., Shelton, S. E., Grundy, E. E., Chiappinelli, K. B., Kamm, R. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37807-z · Cited by 27
Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment
Melo, V. A., Bremer, E., & Martin, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.908389 · Cited by 24
Wang, J., Loeuillard, E. J., Gores, G. J., & Ilyas, S. I. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2010046 · Cited by 20
Esfahani, A. T., Mohammadpour, S., Jalali, P., Yaghoobi, A., Karimpour, R., Torkamani, S. S., Pardakhtchi, A., Salehi, Z., & Mojarad, E. N. (2024) · Scientific Reports · doi:10.1038/s41598-024-61000-x · Cited by 23
“These immunosuppressive effects by tumor cells have been a target of recent treatment strategies to circumvent immunosuppressive tumor microenvironment 67,68 .”
BackgroundPotential target within the tumor microenvironment - MT1-MMP
Liu, J., Li, Y., Lian, X., Zhang, C., Feng, J., Tao, H., & Wang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517519 · Cited by 21
Bersier, L., Lorenzo‐Martín, L. F., Chiang, Y.-H., Durot, S., Czauderna, A., Yarahmadov, T., Wyss, T., Roçi, I., Kim, J., Zamboni, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67169-7 · Cited by 19
“1d) 11 .”
Self-citationETV4 facilitates angiogenesis in hepatocellular carcinoma by upregulating MMP14 expression
Su, H., Shu, S., Tang, W., Zheng, C., Zhao, L., & Fan, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149137 · Cited by 12
Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer
Yu, X., Du, Z., Zhu, P., & Liao, B. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00568-7 · Cited by 11
“One study showed that VEGFA significantly inhibits the killing impact of T cells on colon cancer cells [82].”
Carbajo‐García, M. C., de Miguel–Gómez, L., Juárez‐Barber, E., Trelis, A., Monleón, J., Pellicer, A., Flanagan, J. M., & Ferrero, H. (2022) · Biomedicines · doi:10.3390/biomedicines10061279 · Cited by 11
“CD40 has antiangiogenic and pro-immune properties in other tumors [47,48].”
BackgroundDevelopment and clinical application of bispecific antibody in the treatment of colorectal cancer
Balibegloo, M., & Rezaei, N. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1783249 · Cited by 11
Zhang, X., Zhang, G., Sang, S., Fei, Y., Cao, X., Song, W., Liu, F., Che, J., Tao, H., Wang, H., et al. (2024) · eLife · doi:10.7554/elife.99337 · Cited by 12
“…that anti-angiogenic targeted therapy could augment antitumoral immunity and enhance immunotherapy efficacy by targeting tumor angiogenesis, exhausted T cells proliferation and myeloid cell inflammation ( Zhu et al., 2022 ; Fukumura et al., 2018 ; Hegde et al., 2018 ; Ragusa et al., 2020 ).”
Pleckstrin 2 is a potential drug target for colorectal carcinoma with activation of APC/β‑catenin
Chai, B., Guo, Y., Zhu, N., Jia, J., Zhang, Z., Ping, M., Jia, K., Cui, X., & Suo, Y. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12502 · Cited by 7
Consideration on immunotherapy of liver metastases of malignant tumors
Jiang, C., Zhang, Z., & Li, J. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i8.2374 · Cited by 7
“This indicates that VEGF inhibitors may sensitize the antitumor effects of immunotherapy[33].”
An Introduction to Cell Signalling Pathways and Their Dysregulation in Cancer
Talath, S., Wali, A. F., El‐Tanani, M., Al-Dhaheri, Y., Jain, P., & Mottershead, R. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_1 · Cited by 9
Jia, M., Wang, C., Chen, M., Dong, W., Zhang, H., Ou, J., & Wei, Y. (2025) · Talanta · doi:10.1016/j.talanta.2025.128098 · Cited by 6
Yang, J., Xiong, X., Zheng, W., Xu, H., Liao, X., Wei, Q., & Yang, L. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001939 · Cited by 6
“Comparable results for chemotherapy-based combinations [93,94] were demonstrated in a pancreatic cancer model [95] and a chemotherapy-resistant colorectal cancer model [84] (Table 1).”
BackgroundResultThe function of metalloproteinases in pathophysiology of inflammatory bowel disease and colon cancer
Manzanares, L. D., Herrnreiter, C. J., Hirst, J., & Sumagin, R. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf116 · Cited by 6
Hu, L., Dong, H., He, L., Shi, M., Xiang, N., Su, Y., Wang, C., Tian, Y., Hu, Y., Wang, H., et al. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00053 · Cited by 5
Rokavec, M., Özcan, E., Neumann, J. H. L., & Hermeking, H. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0489 · Cited by 4
“Besides PGK, which we described in the results part, another unfavorable prognostic gene MMP conferred chemoresistance in the APCMin-mouse model of intestinal cancer (26).”
BackgroundCives-Losada, C., Soldani, C., Polidoro, M. A., Franceschini, B., Lleo, A., Martino, M. D., & Donadon, M. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.074093 · Cited by 3
“Similarly, clinical studies have demonstrated the benefit of combining anti-PD-1 therapy with anti-angiogenic such as bevacizumab [132] or tyrosine kinase inhibitors (TKIs) such as regorafenib, as they can normalize tumor vasculature which, in turn, relieves hypoxia and allowing greater T-cell…”
An epigenetic switch in vascular phenotype augments anti-tumor immunity
Kim, D. J., McGinty, M. T., Anandh, S., Riedstra, C. P., Sethi, Y. S., Rutkowski, M. R., & Dudley, A. C. (2026) · Angiogenesis · doi:10.1007/s10456-026-10042-y · Cited by 2
“Similarly, combinations of ICB with anti-angiogenic (AA) therapies are beneficial in mice and humans, which has motivated several new clinical trials across a spec - trum of cancer types [10–13].”
The vascular niche: an orchestrator of the spatiotemporal dynamics of distant metastasis
Miao, Q., Chen, R., Zhang, D.-M., Zhang, J.-Q., & Chen, M.-F. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01820-x · Cited by 1
“Collectively, these interactions establish a favorable, immune-permissive niche [190, 191].”
Rokavec, M., Özcan, E., Neumann, J. H. L., & Hermeking, H. (2023) · doi:10.1158/2767-9764.c.6778142.v2
Zhang, X., Zhang, G., Sang, S., Fei, Y., Cao, X., Song, W., Liu, F., Che, J., Tao, H., Wang, H., et al. (2024) · eLife · doi:10.7554/elife.99337.1
Proteolytic Factors in the Tumor Immune Microenvironment
Nishimura, Y., Maeda, M., Kubota, H., Kikuchi, R., & Shimoda, M. (2025) · Springer eBooks · doi:10.1007/978-3-030-80962-1_97-1
Yun, D., Yang, J.-H., Sim, J.-A., Kim, M. J., Park, J. W., Jeong, S. Y., Shin, A., Kweon, S., & Song, N. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06491-6
“Ragusa et al. revealed the mechanism whereby MMP14 contributes to CRC progression [41].”
Zhang, X., Zhang, G., Sang, S., Fei, Y., Cao, X., Song, W., Liu, F., Che, J., Tao, H., Wang, H., et al. (2025) · eLife · doi:10.7554/elife.99337.2
Proteolytic Factors in the Tumor Immune Microenvironment
Nishimura, Y., Maeda, M., Kubota, H., Kikuchi, R., & Shimoda, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_97
Cathepsin S regulates germinal center reactions and anti-tumor humoral responses
Bruand, M., Srivastava, D., Petruzzella, A. S., Petit, M., Mahfoud, S., Katanayeva, N., Kasapoglu, A., Landragin, C., Tavernari, D., Balli, E., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20252463
Self-citationANGPT2 promotes angiogenesis and immunosuppressive microenvironment in colorectal cancer
Chen, C., Wei, S., Peng, Z., 李少华, Han, L., Fang, W., Cheng, Y., Zheng, J., & Wang, A. (2026) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2025-1-965
Metadata
- Authors
- Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., Lutolf, M. P., Perentes, J., Corse, E., Bianchi, R., Wetterwald, L., Kim, J., Oliver, G., Delorenzi, M., De Palma, M., & Petrova, T. V.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- École Polytechnique Fédérale de Lausanne (CH)
- University of Zurich (CH)
- F. Hoffmann-La Roche AG (CH)
- Northwestern University (US)
- Corresponding author
- Petrova, Tatiana V.
- ORCID
- Ragusa, Simone
- Prat-Luri, Borja
- González-Loyola, Alejandra
- Nassiri, Sina
- Squadrito, Mario Leonardo
- Guichard, Alan
- Cavin, Sabrina
- Gjorevski, Nikolce
- Barras, David
- Marra, Giancarlo
- Perentes, Jean
- Corse, Emily
- Bianchi, Roberta
- Wetterwald, Laureline
- Kim, Jaeryung
- Oliver, Guillermo
- Delorenzi, Mauro
- De Palma, Michele
- Petrova, Tatiana V.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1199-1216
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269598
- OpenAlex
- W3004730319
- Cited by
- 56
- References
- 82
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 4
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Swiss Cancer League (KLS 3406-02-2016, KFS-3759-08-2015)
- MEDIC Foundation (Not available)
- Fondation de lutte contre le cancer (N/A)
- Roche (N/A)
- Swiss Bridge Foundation (N/A)
- N/A (N/A)
- San Salvatore Foundation (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- colorectal cancer, desmoplasia, chemoresistance, Prox1, APC mutation, Wnt signaling, MMP-14, tumor stroma, angiopoietin-2, CD40 agonist, tumor fibrosis, T cell immunity, tumor angiogenesis
- MeSH terms
- Antineoplastic Agents, Immunological, Prospero-Related Homeobox 1 Protein, Animals, Cell Line, Humans, Immunotherapy, Neoplasms, Experimental, Neovascularization, Pathologic, Colorectal Neoplasms, Homeodomain Proteins, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Tumor Suppressor Proteins, Adenomatous Polyposis Coli Protein, Vascular Endothelial Growth Factor A, Angiopoietin-2, Mice, Matrix Metalloproteinase 14
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.